Ozempic and Mounjaro demand surges in India as doctors warn of misuse and unsafe marketing

Doctors say weak oversight is fueling dangerous shortcuts

India’s appetite for weight-loss injectables like Ozempic and Mounjaro is rising fast, with consumers seeking gradual weight reduction. But healthcare professionals are warning that the current regulatory and marketing environment is not keeping pace, increasing the risk of misuse and improper promotion. Calls are growing for stronger oversight to protect patients.